Aeed P A, Welch D R
Department of Cancer and Infectious Diseases Research, Upjohn Company, Kalamazoo, Michigan 49001.
Br J Cancer. 1988 Dec;58(6):746-52. doi: 10.1038/bjc.1988.302.
Using a recently developed model for studying the biology of locally recurrent (LR) mammary tumours in the 13762NF rat mammary adenocarcinoma system, we examined the sensitivity to polymorphonuclear cell, macrophage and natural killer cell cytolysis. The parental MTF7(T20) cell line; the 'primary' tumours which arose following subcutaneous inoculation into the mammary fat pad, sc1 and sc3; and the local recurrences (following surgical excision) LR1 and LR1a from sc1, and LR3 from sc3 were all cells generally resistant to specific PMN cytolysis. LPS-activated macrophages caused 25.1%, 38.7% and 58.8% specific cytolysis in MTF7, sc1 and LR1 cells, respectively at E:T of 20:1 and 72 h co-incubation. LR1a, sc3 and LR3 lysis ranged from 0-4.4% under the same conditions. Non-activated macrophages did not lyse any of the cell lines. Locally recurrent and 'primary' tumour cell lines were also not lysed by naive NK cells (range 0.5-4.0% cytolysis). NK cells activated with bropirimine, a potent immunomodulator currently being studied in clinical trials, and/or interleukin-2 were mildly more effective at killing LR cells. Our results show that locally recurrent tumours exhibit heterogeneous sensitivities and are different from 'primary' tumour cells in sensitivities to immune cell killing, but they are not necessarily more or less sensitive. Results with bropirimine-activated or IL-2-activated NK cells emphasize that nonspecific activation is insufficient to eliminate all tumour subpopulations.
利用最近开发的一种模型,在13762NF大鼠乳腺腺癌系统中研究局部复发性(LR)乳腺肿瘤的生物学特性,我们检测了其对多形核细胞、巨噬细胞和自然杀伤细胞溶解作用的敏感性。亲本MTF7(T20)细胞系;皮下接种到乳腺脂肪垫后产生的“原发性”肿瘤sc1和sc3;以及sc1的局部复发肿瘤(手术切除后)LR1和LR1a,和sc3的LR3,这些细胞通常对特异性PMN细胞溶解具有抗性。在E:T为20:1且共孵育72小时的条件下,LPS激活的巨噬细胞分别在MTF7、sc1和LR1细胞中引起25.1%、38.7%和58.8%的特异性细胞溶解。在相同条件下,LR1a、sc3和LR3的细胞溶解率在0 - 4.4%之间。未激活的巨噬细胞不会溶解任何细胞系。局部复发和“原发性”肿瘤细胞系也不会被未致敏的NK细胞溶解(细胞溶解率范围为0.5 - 4.0%)。用目前正在临床试验中研究的强效免疫调节剂溴匹立明和/或白细胞介素-2激活的NK细胞在杀伤LR细胞方面略有效果。我们的结果表明,局部复发性肿瘤表现出异质性敏感性,在对免疫细胞杀伤的敏感性方面与“原发性”肿瘤细胞不同,但它们不一定更敏感或更不敏感。溴匹立明激活或IL - 2激活的NK细胞的结果强调,非特异性激活不足以消除所有肿瘤亚群。